Drug Guide

Generic Name

Enalapril Maleate and Hydrochlorothiazide

Brand Names Vaseretic, Enalapril Maleate And Hydrochlorothiazide

Classification

Therapeutic: Antihypertensive

Pharmacological: ACE inhibitor and Thiazide diuretic

FDA Approved Indications

Mechanism of Action

Enalapril inhibits angiotensin-converting enzyme (ACE), lowering angiotensin II levels, leading to vasodilation and reduced blood pressure; Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules of the kidney, promoting diuresis and lowering blood pressure.

Dosage and Administration

Adult: Typically, 1 tablet once daily, dosage adjusted based on response.

Pediatric: Not approved for pediatric use.

Geriatric: Start at lower doses due to increased sensitivity and renal function decline.

Renal Impairment: Adjust dosage based on renal function, monitor closely.

Hepatic Impairment: Use with caution; no specific dosage adjustment noted.

Pharmacokinetics

Absorption: Both drugs are well absorbed orally.

Distribution: Predominantly bound to plasma proteins.

Metabolism: Enalapril is converted to enalaprilat in the liver; hydrochlorothiazide minimally metabolized.

Excretion: Renally excreted; enalaprilat retains activity; hydrochlorothiazide excreted unchanged.

Half Life: Enalapril: approx. 11 hours; Hydrochlorothiazide: approx. 6-15 hours.

Contraindications

Precautions

Adverse Reactions - Common

Adverse Reactions - Serious

Drug-Drug Interactions

Drug-Food Interactions

Drug-Herb Interactions

Nursing Implications

Assessment: Monitor blood pressure, renal function, serum electrolytes, signs of angioedema.

Diagnoses:

  • Ineffective tissue perfusion related to hypotension or edema.
  • Electrolyte imbalance.

Implementation: Administer as prescribed, monitor vital signs and labs, educate patient on signs of adverse effects.

Evaluation: Assess blood pressure response, renal function, electrolytes, and patient adherence.

Patient/Family Teaching

Special Considerations

Black Box Warnings:

Genetic Factors: Caution in individuals with genetic predispositions to angioedema.

Lab Test Interference: May increase serum creatinine and potassium.

Overdose Management

Signs/Symptoms: Severe hypotension, electrolyte disturbances.

Treatment: Administer intravenous fluids, vasopressors if needed, monitor electrolytes, and support vitals as necessary.

Storage and Handling

Storage: Store at room temperature, 15–30°C (59–86°F).

Stability: Stable for shelf life when stored properly.

This guide is for educational purposes only and is not intended for clinical use.